Compare FLUX & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLUX | CELU |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.4M | 34.5M |
| IPO Year | N/A | N/A |
| Metric | FLUX | CELU |
|---|---|---|
| Price | $1.51 | $1.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $6.00 | $6.00 |
| AVG Volume (30 Days) | ★ 219.4K | 64.0K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $63,484,000.00 | $40,578,000.00 |
| Revenue This Year | $0.18 | N/A |
| Revenue Next Year | $29.72 | $76.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.13 | N/A |
| 52 Week Low | $1.15 | $1.00 |
| 52 Week High | $7.55 | $4.35 |
| Indicator | FLUX | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 47.66 | 45.46 |
| Support Level | $1.40 | $1.25 |
| Resistance Level | $1.60 | $1.37 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 64.48 | 77.94 |
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.